Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
PHAT | US
-0.46
-3.78%
Healthcare
Biotechnology
30/06/2024
24/04/2026
11.70
12.19
12.26
11.36
Phathom Pharmaceuticals Inc. biopharmaceutical company focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States Europe and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals Inc. was incorporated in 2018 and is headquartered in Florham Park New Jersey.
View LessLow Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Strong Sharpe Ratio (> 1.2)
Weakness based on declining price with high volume
Price Below SMA10D
Smallcap (300M - 2B USD)
High Short percentage (> 15%)
Rich in Valuation (Price to Book > 8)
Weak Operating Margin (< 10%)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
61.7%1 month
56.8%3 months
62.9%6 months
61.0%-
-
25.37
-2.17
1.59
-2.20
101.64
-
-252.07M
798.99M
798.99M
-
-1.06K
-
-
-3.49K
15.37
35.61
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
2.31
Range1M
3.46
Range3M
4.53
Rel. volume
1.32
Price X volume
16.72M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| uniQure N.V | QURE | Biotechnology | 18.03 | 878.02M | 2.79% | n/a | 550.36% |
| KalVista Pharmaceuticals Inc | KALV | Biotechnology | 19.63 | 848.32M | 2.88% | n/a | 3.62% |
| Savara Inc | SVRA | Biotechnology | 5.12 | 842.76M | 3.64% | n/a | 26.18% |
| Theravance Biopharma Inc | TBPH | Biotechnology | 16.46 | 805.26M | 0.92% | n/a | 24.09% |
| SPRY | SPRY | Biotechnology | 8.29 | 803.65M | -0.12% | n/a | 0.07% |
| Sensei Biotherapeutics Inc | SNSE | Biotechnology | 31.79 | 799.55M | -2.54% | n/a | 9.67% |
| Arbutus Biopharma Corporation | ABUS | Biotechnology | 4.2 | 792.88M | -1.18% | n/a | 6.09% |
| Omeros Corporation | OMER | Biotechnology | 13.53 | 784.02M | 0.07% | n/a | -356.63% |
| Janux Therapeutics Inc. Common Stock | JANX | Biotechnology | 15.01 | 782.99M | -1.18% | n/a | 3.62% |
| MannKind Corporation | MNKD | Biotechnology | 2.7 | 742.49M | -0.37% | 132.00 | -149.80% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Janus International Group Inc. | JBI | Building Products & Equipment | 5.44 | 790.55M | 1.30% | 11.62 | 116.21% |
| Fox Factory Holding Corp | FOXF | Recreational Vehicles | 17.7 | 737.79M | 2.31% | 42.05 | 64.69% |
| Latham Group Inc. | SWIM | Building Products & Equipment | 6.01 | 694.62M | -0.17% | 65.18 | 77.00% |
| Ennis Inc | EBF | Building Products & Equipment | 20.33 | 528.66M | -1.26% | 13.28 | 2.28% |
| Malibu Boats Inc | MBUU | Recreational Vehicles | 26.1 | 521.76M | -0.91% | n/a | 1.50% |
| MCBC Holdings Inc | MCFT | Recreational Vehicles | 23.53 | 390.77M | -0.88% | 34.27 | 26.82% |
| Camping World Holdings Inc | CWH | Recreational Vehicles | 7.48 | 337.57M | 8.41% | n/a | 3644.76% |
| ACCO Brands Corporation | ACCO | Building Products & Equipment | 3.31 | 317.09M | 1.85% | n/a | 174.23% |
| Marine Products Corporation | MPX | Recreational Vehicles | 7.99 | 277.39M | -0.99% | 13.23 | 0.00% |
| Urban One Inc | UONEK | Broadcasting - Radio | 4.9543 | 262.62M | -0.42% | n/a | 268.43% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -2.20 | 0.53 | Cheaper |
| Ent. to Revenue | 101.64 | 3,967.00 | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 25.37 | 15.55 | Expensive |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 62.87 | 72.80 | Par |
| Debt to Equity | -2.17 | -1.23 | Cheaper |
| Debt to Assets | 1.59 | 0.25 | Expensive |
| Market Cap | 798.99M | 3.66B | Emerging |